Carcinosarcomas Uterine Clinical Trial
Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)
Multicenter phase II study on trabectedin in patients advanced uterine and ovarian carcinosarcoma. Patients will receive trabectedin until disease progression or unacceptable toxicity. Disease response evaluation will be assessed every 9 weeks.
This is a Phase II, multi-centre, single arm study aiming at evaluating efficacy and toxicity
of Trabectedin in a population of advanced or recurrent ovarian and uterine carcinosarcoma.
Trabectedin will be infused at the dose of 1.3 mg/m2 as a 3- hour iv infusion every 3 weeks via a central venous catheter. ;
|Source||Fondazione Policlinico Universitario Agostino Gemelli IRCCS|
|Status||Active, not recruiting|
|Start date||February 22, 2017|
|Completion date||March 2021|